We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Syntheticmr Ab (publ) | LSE:0G79 | London | Ordinary Share | SE0015987946 | SYNTHETICMR ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 350.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | 89.21M | 10.01M | 0.2404 | 1,455.91 | 14.58B |
From May 2019 to May 2024
STOCKHOLM, Nov. 9, 2020 /PRNewswire/ -- Dr Rovira is Head of Neuroradiology at Vall d'Hebron Hospital in Barcelona and a Professor of Radiology and Neuroimmunology. He is specialized in diagnostic neuroradiology with particular interest in demyelinating diseases, stroke, neuro-oncology and head and neck tumors. He is past president of the European Society of Neuroradiology and served as Co-Chairman of MAGNIMS (European Multicenter Collaborative Research Network on MRI in MS). He is on the editorial boards of Neurology, Neuroradiology and MS Forum, and member of the International Advisory Board on Clinical Trials in MS.
"I have collaborated with SyntheticMR for a few years now and I am a strong believer in the benefits of quantitative MRI," says Dr Rovira. "I look forward to working with the team at SyntheticMR to create a robust and clinically valuable product that can benefit our patients."
"Dr Rovira has provided valuable guidance to us at SyntheticMR in the past, and we are pleased to welcome him to our newly established Medical Advisory Board," says Ulrik Harrysson, CEO SyntheticMR. "We work hard to ensure we deliver products and features that are robust and reliable, of high quality and with clear clinical value. Dr Rovira's extensive experience will be important for us as we continue to develop our product within neuroradiology."
CONTACT:
For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 ulrik.harrysson@syntheticmr.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/syntheticmr-ab/r/dr--alex-rovira-from-hospital-vall-d-hebron-joins-syntheticmr-s-medical-advisory-board,c3228728
The following files are available for download:
https://mb.cision.com/Main/11663/3228728/1329156.pdf | Release |
https://news.cision.com/syntheticmr-ab/i/alex-2019,c2845130 | Alex 2019 |
View original content:http://www.prnewswire.com/news-releases/dr-alex-rovira-from-hospital-vall-dhebron-joins-syntheticmrs-medical-advisory-board-301168509.html
SOURCE SyntheticMR AB
Copyright 2020 PR Newswire
1 Year Syntheticmr Ab (publ) Chart |
1 Month Syntheticmr Ab (publ) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
